Measurement of ab-initio physiomarker using wearable sensors to predict aneurysm growth and formation

项目摘要 动脉瘤是血管的永久性局部扩张。生长、破裂和 主动脉瘤的夹层会导致很大的患者死亡率。海流 护理标准依赖于在1至5年内进行被动监测的战略，以 监测动脉瘤的生长速度。该项目试图验证预测的准确性 从头算生理标记物在诊断动脉瘤生长和夹层中的应用 初步评估。通过捕捉导致动脉瘤的潜在物理机制 发展起来，生理标记物可以用来确定血液的一个横截面是否 血管将永久扩张--动脉瘤是会随着时间的推移增长还是保持停滞。 这种预见性策略可以在一开始就为立即治疗或外科干预提供信息 对患者进行评估，而不是等到随访时才监测生长情况。具体的 该项目的目标有三个。首先是验证人工关节的生物力学准确性。 生理标记物，确定其与组织重塑模式的关系，并量化 使用已建立的体外实验的非线性效应。血流动力学与血管壁 房地产将受到控制，以检查增长和停滞制度。第二个是 验证生理标记物在马凡等相关大动脉病变患者中的准确性 综合征或二尖瓣，这通常可能是 基于回归的方法，但预计不会影响这一从头算框架。回顾 将进行观察性研究，以检验生理标记物在 这些因素的存在。最后，将使用灵活的、可穿戴的 传感器可以与超声心动图结合使用，也可以作为独立的平台使用。这将是 通过仔细控制的前瞻性观察研究进行，历时1至2年。两者都有 医疗模式将提供一种更安全、更廉价和更准确的方法来预测动脉瘤的增长和 解剖。如果独立传感器平台显示出足够的精度来测量 Physiomarker，它将允许更频繁地在家中监测动脉瘤，类似于如何 血压监测仪可以用来跟踪高血压的发展。此外，它还 将能够在普通人群中进行更广泛的动脉瘤筛查，作为常规的一部分 体检。

Project Summary Aneurysms are permanent, local dilations of the blood vessel. The growth, rupture and dissection of aortic aneurysms induce a significant rate of patient mortality. The current standard of care relies on a reactive strategy of surveillance over a period of 1 to 5 years to monitor the growth rate of an aneurysm. This project seeks to validate the predictive accuracy of an ab-initio physiomarker in diagnosing both the growth and dissection of an aneurysm during an initial evaluation. By capturing the underlying physical mechanism driving aneurysm development, the physiomarker can be used to determine whether a cross section of the blood vessel will dilate permanently—whether an aneurysm will grow or remain stagnant over time. This predictive strategy can inform immediate treatment or surgical intervention at the initial evaluation of the patient instead of waiting until follow-up to monitor for growth. The specific aims of the project are threefold. The first is to verify the biomechanical accuracy of the physiomarker, determine its relationship with tissue remodeling modalities, and quantify nonlinear effects using an established in vitro experiment. The hemodynamic and vessel wall properties will be controlled to examine the growth and stagnation regimes. The second is to validate the accuracy of the physiomarker in patients with associated aortopathies like Marfan syndrome or biscuspid aortic valves, which may typically act as confounding factors for regression-based methods but are not expected to affect this ab-initio framework. Retrospective observational studies will be performed to examine the accuracy of the physiomarker in the presence of these factors. Lastly, the physiomarker will be measured using flexible, wearable sensors, either in conjunction with echocardiography or as a standalone platform. This will be carried out via carefully controlled, prospective observational studies over 1 to 2 years. Both modalities will offer a safer, cheaper and more accurate way to predict aneurysm growth and dissection. If the standalone sensor platform exhibits sufficient accuracy in measuring the physiomarker, it will enable more frequent, at home monitoring of aneurysms, akin to how blood pressure monitors can be used to track the development of hypertension. Additionally, it will enable much broader screening for aneurysms in the general population as part of routine health checkups.